This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Celloram Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Seunghwan Lim: Innovator in Fatty Acid Metabolism Treatments
Introduction
Seunghwan Lim is a notable inventor based in Solon, OH (US). He has made significant contributions to the field of pharmaceutical compositions, particularly in the area of fatty acid metabolism. His work focuses on developing innovative solutions for treating diseases related to this critical metabolic pathway.
Latest Patents
Seunghwan Lim holds 1 patent for his invention titled "FABP4/5 inhibitors, methods of use and methods of making." This patent discloses FABP4 and FABP5 inhibitor compounds and their applications in pharmaceutical compositions aimed at treating diseases associated with fatty acid metabolism, including cancer. Additionally, the patent outlines methods for preparing these compounds, showcasing Lim's commitment to advancing medical science.
Career Highlights
Seunghwan Lim is currently employed at Celloram Inc., where he continues to innovate and contribute to the field of biopharmaceuticals. His expertise in fatty acid metabolism has positioned him as a valuable asset in the research and development of new therapeutic strategies.
Collaborations
Throughout his career, Seunghwan Lim has collaborated with talented individuals such as Tej Pareek and Elizabeth Meyers. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in their field.
Conclusion
Seunghwan Lim's work in developing FABP4 and FABP5 inhibitors represents a significant advancement in the treatment of diseases related to fatty acid metabolism. His contributions to Celloram Inc. and the broader scientific community highlight the importance of innovation in addressing complex health challenges.